By decisions dated 30 July 2018, then confirmed in the appeal by decisions dated 30 August 2018, the Court of Milan dismissed PI requested by ICOS and its licensee Eli Lilly against Sandoz, ascertaining the prima ...

Diverging from the previous decision, the Court pointed out that the relevance of the file history to construe the scope of protection of a patent and then the infringement of equivalence has to be carefully and ...

This is another decision in the long-running series of patent cases regarding the anti-cancer drug pemetrexed (Alimta®).

By an order dated 17 October 2016, the Court of Milan confirmed that a trade mark proprietor can enforce its right to oppose the sale of parallel imported goods which were put on the market in the country of export ...

On 18 October 2016 the Italian Senate approved bill no. 2524 on ratification of the Unified Patent Court Agreement ("UPCA"), which had previously passed through the Italian Chamber of Deputies on 15 September 2016 ...

In 2012 Italy implemented a rule - Article 11 of the so-called "Balduzzi Decree", converted into Law no. 189/2012 – which provides that generic products cannot be classified as reimbursed [reimbursable?] by the ...

In July 2014 the Court of Milan filed two judgments declaring the invalidity of the Italian supplementary protection certificate ("SPC") on the combination of telmisartan and hydrochlorothiazide ("HCTZ") (the ...

The decision no. 693/214 of the Consiglio di Stato (Italy's highest administrative Court) filed on February 12, 2014 closed the saga of the Xalatan case in Italy, ruling that Pfizer had abused its dominant position.